ReNeuron Group PLC

ReNeuron Group encouraged by level of interest in its key programmes

ReNeuron Group PLC's (LON:RENE) Michael Hunt chats to Proactive London's Andrew Scott following the release of its year-end update.

The cell therapy specialist has two clinical trials underway and is looking at partnerships or licensing deals for its three major programmes.

Hunt says with a partnership deal for its cell technology in China now secured they're pursuing other collaborations or out-licensing deals across all its programmes.

Quick facts: ReNeuron Group PLC

Price: £2.05

Market: LSE
Market Cap: £65.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom. Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the...

4 weeks, 1 day ago

2 min read